128 related articles for article (PubMed ID: 20051287)
1. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Woelber L; Mueller V; Eulenburg C; Schwarz J; Carney W; Jaenicke F; Milde-Langosch K; Mahner S
Gynecol Oncol; 2010 May; 117(2):183-8. PubMed ID: 20051287
[TBL] [Abstract][Full Text] [Related]
2. Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Kock L; Mahner S; Choschzick M; Eulenburg C; Milde-Langosch K; Schwarz J; Jaenicke F; Müller V; Woelber L
Int J Gynecol Cancer; 2011 Jan; 21(1):141-8. PubMed ID: 21330838
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Woelber L; Kress K; Kersten JF; Choschzick M; Kilic E; Herwig U; Lindner C; Schwarz J; Jaenicke F; Mahner S; Milde-Langosch K; Mueller V; Ihnen M
BMC Cancer; 2011 Jan; 11():12. PubMed ID: 21223596
[TBL] [Abstract][Full Text] [Related]
4. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Choschzick M; Oosterwijk E; Müller V; Woelber L; Simon R; Moch H; Tennstedt P
Virchows Arch; 2011 Aug; 459(2):193-200. PubMed ID: 21691815
[TBL] [Abstract][Full Text] [Related]
6. Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Schütze D; Milde-Langosch K; Witzel I; Rody A; Karn T; Schmidt M; Choschzick M; Jänicke F; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):747-54. PubMed ID: 23358720
[TBL] [Abstract][Full Text] [Related]
7. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Brown-Glaberman U; Marron M; Chalasani P; Livingston R; Iannone M; Specht J; Stopeck AT
Dis Markers; 2016; 2016():9810383. PubMed ID: 26941473
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Yang JS; Chen MK; Yang SF; Chang YC; Su SC; Chiou HL; Chien MH; Lin CW
Clin Chem Lab Med; 2014 Sep; 52(9):1367-77. PubMed ID: 24695043
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
[TBL] [Abstract][Full Text] [Related]
11. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.
Hektoen HH; Flatmark K; Andersson Y; Dueland S; Redalen KR; Ree AH
BMC Cancer; 2015 Jul; 15():543. PubMed ID: 26205955
[TBL] [Abstract][Full Text] [Related]
12. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
[TBL] [Abstract][Full Text] [Related]
13. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
15. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
17. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Ilie M; Mazure NM; Hofman V; Ammadi RE; Ortholan C; Bonnetaud C; Havet K; Venissac N; Mograbi B; Mouroux J; Pouysségur J; Hofman P
Br J Cancer; 2010 May; 102(11):1627-35. PubMed ID: 20461082
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Malentacchi F; Simi L; Nannelli C; Andreani M; Janni A; Pastorekova S; Orlando C
Lung Cancer; 2009 Jun; 64(3):271-6. PubMed ID: 19022520
[TBL] [Abstract][Full Text] [Related]
19. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Korkolopoulou P; Perdiki M; Thymara I; Boviatsis E; Agrogiannis G; Kotsiakis X; Angelidakis D; Rologis D; Diamantopoulou K; Thomas-Tsagli E; Kaklamanis L; Gatter K; Patsouris E
Hum Pathol; 2007 Apr; 38(4):629-38. PubMed ID: 17367605
[TBL] [Abstract][Full Text] [Related]
20. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
